Management of Apixaban-Associated Gastrointestinal Bleeding

Initial Management

• The American College of Emergency Physicians recommends holding apixaban and consulting gastroenterology as the most appropriate initial care step for hemodynamically stable patients with painless hematochezia on apixaban 1
• The International Society on Thrombosis and Haemostasis suggests that andexanet alfa is reserved exclusively for life-threatening, uncontrolled bleeding, not for stable gastrointestinal bleeding 2, 1

Reversal Agents

• The American Heart Association notes that andexanet alfa achieved 93% reduction in anti-Xa activity and 80% hemostatic efficacy at 12 hours in patients with major bleeding, but was studied in patients with hemodynamic compromise 2
• The American College of Cardiology reports that thromboembolic events occurred in 10.3% of patients receiving andexanet versus 5.6% with usual care, representing an absolute increase of 4.6 per 100 patients 2

Renal Function Assessment

• The American Heart Association recommends that renal function assessment is essential, as declining renal function increases apixaban accumulation and bleeding risk 3, 4

Resumption of Anticoagulation

• The American College of Cardiology suggests that the timing of apixaban resumption depends on adequacy of hemostasis, severity of the bleeding episode, and stroke risk (CHA₂DS₂-VASc score assessment) 4
• The European Society of Cardiology recommends resuming apixaban as soon as adequate hemostasis is established, without waiting for a specific time interval, as the thromboembolic risk in atrial fibrillation patients is substantial 5